Raymond James & Associates’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $575M | Buy |
6,391,865
+145,504
| +2% | +$12.2M | 0.35% | 53 |
|
|
2024
Q2 | $492M | Buy |
6,246,361
+336,618
| +6% | +$27.6M | 0.32% | 56 |
|
|
2024
Q1 | $515M | Sell |
5,909,743
-13,130
| -0.2% | -$1.12M | 0.35% | 50 |
|
|
2023
Q4 | $488M | Sell |
5,922,873
-203,556
| -3% | -$15.5M | 0.36% | 50 |
|
|
2023
Q3 | $480M | Buy |
6,126,429
+305,956
| +5% | +$25.6M | 0.4% | 46 |
|
|
2023
Q2 | $513M | Buy |
5,820,473
+266,199
| +5% | +$22.9M | 0.42% | 43 |
|
|
2023
Q1 | $448M | Buy |
5,554,274
+851,151
| +18% | +$69.4M | 0.39% | 46 |
|
|
2022
Q4 | $366M | Buy |
4,703,123
+358,335
| +8% | +$29M | 0.34% | 55 |
|
|
2022
Q3 | $351M | Sell |
4,344,788
-47,781
| -1% | -$4.29M | 0.35% | 52 |
|
|
2022
Q2 | $394M | Sell |
4,392,569
-109,610
| -2% | -$11.1M | 0.39% | 47 |
|
|
2022
Q1 | $500M | Buy |
4,502,179
+166,047
| +4% | +$17.5M | 0.42% | 41 |
|
|
2021
Q4 | $449M | Buy |
4,336,132
+118,032
| +3% | +$13.7M | 0.36% | 51 |
|
|
2021
Q3 | $529M | Buy |
4,218,100
+99,342
| +2% | +$12.9M | 0.47% | 33 |
|
|
2021
Q2 | $511M | Buy |
4,118,758
+70,443
| +2% | +$8.84M | 0.47% | 34 |
|
|
2021
Q1 | $478M | Buy |
4,048,315
+23,064
| +0.6% | +$2.7M | 0.48% | 33 |
|
|
2020
Q4 | $472M | Buy |
4,025,251
+37,140
| +0.9% | +$4.09M | 0.52% | 31 |
|
|
2020
Q3 | $414M | Buy |
3,988,111
+20,755
| +0.5% | +$2.08M | 0.52% | 36 |
|
|
2020
Q2 | $364M | Buy |
3,967,356
+114,213
| +3% | +$11M | 0.49% | 36 |
|
|
2020
Q1 | $347M | Buy |
3,853,143
+45,545
| +1% | +$4.85M | 0.55% | 30 |
|
|
2019
Q4 | $432M | Buy |
3,807,598
+195,363
| +5% | +$21.4M | 0.55% | 32 |
|
|
2019
Q3 | $392M | Buy |
3,612,235
+182,439
| +5% | +$19M | 0.55% | 29 |
|
|
2019
Q2 | $334M | Buy |
3,429,796
+1,714,620
| +100% | +$157M | 0.48% | 34 |
|
|
2019
Q1 | $156M | Buy |
1,715,176
+135,179
| +9% | +$12.1M | 0.24% | 76 |
|
|
2018
Q4 | $144M | Buy |
1,579,997
+30,423
| +2% | +$2.84M | 0.25% | 77 |
|
|
2018
Q3 | $152M | Buy |
1,549,574
+145,046
| +10% | +$13.4M | 0.24% | 82 |
|
|
2018
Q2 | $120M | Buy |
1,404,528
+185,164
| +15% | +$15.5M | 0.2% | 95 |
|
|
2018
Q1 | $97.8M | Buy |
1,219,364
+89,217
| +8% | +$7.36M | 0.18% | 109 |
|
|
2017
Q4 | $91.3M | Buy |
1,130,147
+12,325
| +1% | +$987K | 0.17% | 111 |
|
|
2017
Q3 | $86.9M | Buy |
1,117,822
+1,734
| +0.2% | +$144K | 0.17% | 117 |
|
|
2017
Q2 | $99.1M | Sell |
1,116,088
-31,525
| -3% | -$2.66M | 0.21% | 96 |
|
|
2017
Q1 | $92.5M | Buy |
1,147,613
+72,924
| +7% | +$5.7M | 0.21% | 94 |
|
|
2016
Q4 | $76.6M | Sell |
1,074,689
-56,453
| -5% | -$4.44M | 0.2% | 110 |
|
|
2016
Q3 | $97.7M | Buy |
1,131,142
+306,748
| +37% | +$26.7M | 0.27% | 70 |
|
|
2016
Q2 | $71.5M | Buy |
824,394
+74,487
| +10% | +$6.02M | 0.22% | 92 |
|
|
2016
Q1 | $56.2M | Sell |
749,907
-46,507
| -6% | -$3.5M | 0.19% | 108 |
|
|
2015
Q4 | $61.3M | Buy |
796,414
+52,418
| +7% | +$3.95M | 0.22% | 89 |
|
|
2015
Q3 | $49.8M | Buy |
743,996
+21,946
| +3% | +$1.62M | 0.2% | 102 |
|
|
2015
Q2 | $53.5M | Buy |
722,050
+92,311
| +15% | +$7.05M | 0.21% | 100 |
|
|
2015
Q1 | $49.1M | Buy |
629,739
+360,335
| +134% | +$27.3M | 0.22% | 92 |
|
|
2014
Q4 | $19.5M | Buy |
269,404
+80,737
| +43% | +$5.61M | 0.1% | 231 |
|
|
2014
Q3 | $11.7M | Buy |
188,667
+14,798
| +9% | +$941K | 0.07% | 312 |
|
|
2014
Q2 | $11.1M | Sell |
173,869
-17,735
| -9% | -$1.08M | 0.07% | 317 |
|
|
2014
Q1 | $11.8M | Buy |
191,604
+23,228
| +14% | +$1.35M | 0.08% | 275 |
|
|
2013
Q4 | $9.66M | Sell |
168,376
-165,053
| -50% | -$9.36M | 0.07% | 307 |
|
|
2013
Q3 | $17.8M | Sell |
333,429
-48,664
| -13% | -$2.62M | 0.15% | 130 |
|
|
2013
Q2 | $19.7M | Buy |
+382,093
| New | +$18.9M | 0.19% | 108 |
|
Other funds holding MDT
Raymond James & Associates's MDT Position: Q3 2024 in Review
Raymond James & Associates increased its Medtronic (MDT) stake by 2.3% in Q3 2024, buying an estimated $12.2M and bringing the position to 6,391,865 shares worth $575M. The position accounts for 0.35% of the portfolio, ranked #53.
Raymond James & Associates first reported a position in MDT in Q2 2013 and has held it in 46 quarters since. 2,063 funds tracked by Wall St. Rank hold MDT as of Q3 2024.
- Raymond James & Associates held 6,391,865 shares of Medtronic worth $575M as of Q3 2024.
- Raymond James & Associates bought 145,504 Medtronic shares in Q3 2024, an estimated $12.2M.
- Medtronic made up 0.35% of Raymond James & Associates's portfolio in Q3 2024, its #53 holding.
- Raymond James & Associates first reported a position in Medtronic in Q2 2013 and has held it in 46 quarters since.
- 2,063 funds tracked by Wall St. Rank held Medtronic as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.